Dare Bioscience Inc (DARE)
0.4133
-0.02
(-4.02%)
USD |
NASDAQ |
May 31, 16:00
0.41
0.00 (0.00%)
After-Hours: 20:00
Dare Bioscience Cash from Financing (Quarterly): 0.014M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.014M |
| December 31, 2023 | 5.309M |
| September 30, 2023 | 8.576M |
| June 30, 2023 | 0.4522M |
| March 31, 2023 | 1.299M |
| December 31, 2022 | -0.00 |
| September 30, 2022 | 0.0045M |
| June 30, 2022 | 1.339M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 16.00M |
| September 30, 2021 | 35.22M |
| June 30, 2021 | 13.25M |
| March 31, 2021 | 11.37M |
| December 31, 2020 | 8.455M |
| September 30, 2020 | 5.399M |
| June 30, 2020 | 4.390M |
| March 31, 2020 | 6.888M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 5.152M |
| March 31, 2019 | 0.00 |
| December 31, 2018 | -0.0025M |
| September 30, 2018 | -0.0812M |
| Date | Value |
|---|---|
| June 30, 2018 | -0.0022M |
| March 31, 2018 | 10.20M |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.055M |
| March 31, 2017 | 0.10M |
| December 31, 2016 | 0.1975M |
| September 30, 2016 | 3.859M |
| June 30, 2016 | -1.968M |
| March 31, 2016 | -1.891M |
| December 31, 2015 | 6.60M |
| September 30, 2015 | 0.156M |
| June 30, 2015 | 37.26M |
| March 31, 2015 | 13.11M |
| December 31, 2014 | -0.895M |
| September 30, 2014 | -0.849M |
| June 30, 2014 | 60.03M |
| March 31, 2014 | 6.65M |
| December 31, 2013 | -1.149M |
| September 30, 2013 | 8.046M |
| June 30, 2013 | -0.763M |
| March 31, 2013 | -0.732M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Dec 2022
35.22M
Maximum
Sep 2021
6.156M
Average
4.771M
Median
Cash from Financing (Quarterly) Benchmarks
| Altimmune Inc | -0.261M |
| Verastem Inc | 0.846M |
| Oragenics Inc | 1.653M |
| Actinium Pharmaceuticals Inc | 14.77M |
| Orgenesis Inc | 3.614M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.813M |
| Cash from Investing (Quarterly) | -0.0073M |
| Free Cash Flow | -30.19M |
| Free Cash Flow Per Share (Quarterly) | -0.0679 |
| Free Cash Flow to Equity (Quarterly) | -6.820M |
| Free Cash Flow Yield | -79.93% |